ATAI Life Sciences BV

Stock Chart, Company Information, and Scan Results

$3.56(as of Jul 23, 11:02 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

ATAI Life Sciences BV Company Information, Fundamentals, and Technical Indicators

Stock Price$3.56
Ticker SymbolATAI
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees54
CountyUSA
Market Cap$748.9M
EBIDTA-96.3M
10-Day Moving Average2.92
P/E Ratio-4.18
20-Day Moving Average2.69
Forward P/E Ratio0.00
50-Day Moving Average2.32
Earnings per Share-0.91
200-Day Moving Average1.69
Profit Margin-1,699.74%
RSI77.38
Shares Outstanding212.1M
ATR0.23
52-Week High3.60
Volume5,601,254
52-Week Low1.03
Most Recent Support Level2.58
Book Value152.3M
Most Recent Resistance Level3.60
P/B Ratio4.09
Upper Keltner3.21
P/S Ratio334.00
Lower Keltner2.17
Debt-to-Equity Ratio3.21
Next Earnings Date08/18/2025
Cash Surplus19.8M
Next Ex-Dividend DateUnknown

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.

ATAI Life Sciences BV In Our Stock Scanner

example chart graphic
Date: Jul 23, 2025Scan Name: Uptrending StocksScan Type: Chart Pattern Scans
As of ---
example chart graphic
Date: Jul 23, 2025Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 23, 2025Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 23, 2025Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 23, 2025Scan Name: Low Debt with 20%+ Return on EquityScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 23, 2025Scan Name: Doji CandlesScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Date: Jul 23, 2025Scan Name: Dragonfly DojiScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Date: Jul 23, 2025Scan Name: Hammer CandleScan Type: Candlestick Pattern Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.